

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/136362/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Domah, Farya, Shah, Raunaq, Nurmatov, Ulugbek B. and Tagiyeva, Nara 2021. The use of low-level laser therapy to reduce postoperative morbidity after third molar surgery: a systematic review and meta-analysis. *Journal of Oral and Maxillofacial Surgery* 79 (2) , 313.E1-313.E19. 10.1016/j.joms.2020.09.018

Publishers page: <http://dx.doi.org/10.1016/j.joms.2020.09.018>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Journal of Oral and Maxillofacial Surgery

## Laser therapy reduces swelling, but not pain or trismus: a systematic review and meta-analysis --Manuscript Draft--

<b>Manuscript Number:</b>	YJOMS-D-20-00976R3
<b>Article Type:</b>	Review Article
<b>Section/Category:</b>	Dentoalveolar Surgery
<b>Keywords:</b>	laser; Third Molar; Pain; swelling; trismus; morbidity
<b>Corresponding Author:</b>	Farya Domah, B.A, B.Dent.Sc, MFDS, MSc University of Birmingham College of Medical and Dental Sciences UNITED KINGDOM
<b>First Author:</b>	Farya Domah, B.A, B.Dent.Sc, MFDS, MSc
<b>Order of Authors:</b>	Farya Domah, B.A, B.Dent.Sc, MFDS, MSc Raunaq Shah, BDS MFDS RCS MSc Prosthodontics Ulugbek Nurmatov, MD, MSc, MPH, MBA, PhD Nara Tagiyeva, PhD MPH MD
<b>Abstract:</b>	<p>Surgical removal of wisdom teeth carries morbidity and significantly affects patients quality of life. This study aims to investigate whether administration of low-level laser therapy (LLLT) is effective in reducing post-operative morbidity in patients undergoing surgical removal of mandibular third molars (MTM) compared to placebo. <b>Material &amp; Methods:</b> A systematic review and meta-analysis involving a comprehensive search strategy implemented across five electronic databases. This was supplemented by hand searching, contacting international experts and grey literature. Titles, abstracts and full articles were scrutinised for studies meeting the inclusion criteria. All randomised controlled trials (RCT) comparing treatment group of LLLT to a placebo control group were eligible for inclusion. The outcomes variables were post-operative pain, swelling and trismus. Risk of bias and methodological quality assessment was carried out. We pooled data statistically and meta-analyses were carried out using a random-effects model. <b>Results;</b> Seventeen RCTs were included in this systematic review, all of which were considered to have a low risk of bias. Participants, aged 13-70, and 35% female, totalled 1064. Meta-analyses found significant reductions in standardised mean differences (SMD) in swelling at day 2 and day 7 postoperatively (SMD -0.611, 95% CI -0.968, -0.234; SMD -0.532, 95% CI -0.795, -0.269). There were non-significant reductions in SMD in pain and trismus at day 2 and day 7 postoperatively. <b>Conclusion;</b> LLLT significantly reduces swelling after extraction of MTM compared to placebo. LLLT has not shown to reduce post-operative pain and trismus. LLLT does not cause adverse effects. There is currently insufficient evidence available, to promote the investment in LLLT versus the net clinical benefit. RCTs with larger sample size and standardised study design and outcome measures are required, to make definitive recommendations to clinicians on its use on patients.</p>

Dear Dr Hupp,

Please can you consider this review article titled: 'The use of laser therapy to reduce postoperative morbidity following third molar surgery. A systematic review and meta-analysis' for publication in the Journal of Oral and Maxillofacial Surgery.

This original article has not been published in another journal nor has it been currently submitted or accepted for publication elsewhere. This systematic review and meta-analysis has been registered on the website of the International Prospective Register of Systematic Reviews; PROSPERO.

(PROSPERO 2018 CRD42018112018. Available from:

[https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42018112018](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018112018))

In consideration of the Journal of Oral and Maxillofacial Surgery taking action in reviewing and editing our submission, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the American Association of Oral and Maxillofacial Surgeons in the event that such work is published in the JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. The undersigned authors understand that if the manuscript is accepted, the Editors reserve the right to determine whether it will be published in the print edition or solely in the Internet edition of the Journal. Articles accepted for publication are subject to editorial revision.

The authors understand that the editor reserves the right to edit manuscripts to fit the space available and to ensure conciseness, clarity, and stylistic consistency.

I remain at your disposal, please do not hesitate to get in contact.

Kind regards,

Farya Domah

**REVISION COVER LETTER**  
**(Ms. Ref. No.: YJOMS-D-20-00976R1)**

Dear Dr Hupp,

Thank you for your comments on the revised manuscript titled "Laser therapy reduces swelling, but not pain or trismus: a systematic review and meta-analysis."

I have made all changes as requested. I have itemised these below:

*(1) Please cite all references in numerical order in the text of the manuscript (Reference #15 does not appear to be cited and references 23, 45, and 46 appear to be out of order)*

The references have been adjusted. #15 error has been removed. Reference 23 has been moved to #31. References 46 and 46 have been changed to cite the 2009 publication before the 2010 publication.

I have uploaded this revision cover letter along with the revised manuscript via the relevant platform.

Thank you for your patience with my hand-written references as I am experiencing difficulties with my referencing software.

I look forward to hearing from you regarding consideration for acceptance for publication.

Kind regards

Farya Domah

## Title page

### Title

The use of laser therapy to reduce postoperative morbidity following third molar surgery. A systematic review and meta-analysis.

### Author name and affiliations

Dr Farya Domah <sup>a</sup>

B.A, B.Dent.Sc, MFDS RCS, MSc

Oral Surgery Specialist Registrar

Department of Oral Surgery, University of Birmingham. 5 Mill Pool Way, Birmingham. B5 7EG. United Kingdom.

[farya.domah@nhs.net](mailto:farya.domah@nhs.net)

+44 121 466 5555

Corresponding author

Dr Raunaq Shah <sup>b</sup>

BDS, MFDS RCS, MJDF RCS, MSc Prosthodontics (Dist), PgDip Implantology

Private dental surgeon

Department of Implantology, College of Medicine & Dentistry, 32-34 Colmore Circus Queensway, Birmingham. B4 6BN. United Kingdom.

[raunaqshah@hotmail.com](mailto:raunaqshah@hotmail.com)

Dr Ulugbek B Nurmatov <sup>c</sup>

MD, MSc, MPH, MBA, PhD.

Research fellow

Division of Population Medicine, School of Medicine, Cardiff University. Neuadd Meirionnydd, Cardiff. CF14 4YS. United Kingdom.

[nurmatovu@cardiff.ac.uk](mailto:nurmatovu@cardiff.ac.uk)

Dr Nara Tagiyeva <sup>d</sup>

PhD, MPH, MD

Director MSc International Public Health

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool. L3 5QA. United Kingdom.

[nara.tagiyeva-milne@lstm.ac.uk](mailto:nara.tagiyeva-milne@lstm.ac.uk)

## **“Laser therapy reduces swelling, but not pain or trismus: a systematic review and meta-analysis”**

### **Abstract**

#### **Purpose**

Surgical removal of third molars carries morbidity and significantly affects patients' quality-of-life. This study aims to investigate whether administration of low-level laser therapy (LLLT) is effective in reducing post-operative morbidity in patients undergoing surgical removal of mandibular third molars (MTM) compared to placebo.

#### **Material & Methods**

A systematic review and meta-analysis involving a comprehensive search strategy implemented across five electronic databases. This was supplemented by hand searching, contacting international experts and grey literature. Titles, abstracts and full articles were scrutinised for studies meeting the inclusion criteria. All randomised controlled trials (RCT) comparing treatment group of LLLT to a placebo control group were eligible for inclusion. The outcomes variables were post-operative pain, swelling and trismus. Risk of bias and methodological quality assessment was carried out. We pooled data statistically and meta-analyses were carried out using a random-effects model.

#### **Results**

Seventeen RCTs were included in this systematic review, all of which were considered to have a low risk of bias. Participants, aged 13-70, and 35% female, totalled 1064. Meta-analyses found significant reductions in standardised mean differences (SMD) in swelling at day 2 and day 7 postoperatively (SMD -0.611, 95% CI -0.968, -0.234; SMD -0.532, 95% CI -0.795, -0.269). There were non-significant reductions in SMD in pain and trismus at day 2 and day 7 postoperatively.

#### **Conclusion**

LLLT significantly reduces swelling after extraction of MTM compared to placebo. LLLT has not shown to reduce post-operative pain and trismus. LLLT does not cause adverse effects. There is currently insufficient evidence available, to promote the investment in LLLT versus the net clinical benefit. RCTs with larger sample size and standardised study design and outcome measures are required, to make definitive recommendations to clinicians on its use on patients.

**Keywords:** laser, third molar, pain, swelling, trismus, morbidity

## INTRODUCTION

### **Description of the condition**

An average of 25% of third molars are impacted and these teeth may require surgical removal<sup>1</sup>. The removal of third molars is not without complications. The general public is well aware of the common risks of third molar removal including pain, swelling and trismus. There are numerous other potential complications associated with removal of third molars; these include temporary or permanent damage to the inferior alveolar nerve, infection, bruising, damage to adjacent teeth, alveolar osteitis and in rare cases - fracture of the mandible<sup>2</sup>.

### **Scale of the problem**

Patients experience significant disturbances in their quality-of-life (QoL) in the five days following third molar surgery<sup>3</sup>. One of the main reasons for patients being unhappy with their surgical treatment is the experience of pain. Also, patients do not respond well to treatment that, albeit temporary, causes them facial deformity in the form of facial swelling. Pain, swelling and trismus arise as a result of an inflammation cascade set off by the surgical procedure<sup>4</sup>. Traditional methods for minimising the sequelae of post-operative pain, swelling and trismus include the use of analgesia, corticosteroids and cryotherapy. However, these modes all have varying degrees of side effects. Alternative efficacious methods have been welcomed; such as low-level laser therapy (LLLT). The beneficial effects of lasers on human tissue were recognized in the 1960s and introduced in the medical field<sup>5</sup>.

A high number of in-vitro studies found that low level lasers are capable of influencing pain levels by a sequence of events; downregulation of biochemical proteins such as prostaglandins (PGE<sub>2</sub>), interleukins (IL-1), tumor necrosis factor, inhibition of cyclo-oxygenase-2 and influencing redox reactions at a cellular level<sup>6</sup>. Also, by decreasing vessel size and permeability, the influx of pro-inflammatory cytokines is controlled and thus the inflammatory phase is less acute<sup>1</sup>. Another effect of

1 laser is that it alters the central uptake and release of serotonin and acetylcholine and stimulates the  
2 production of endorphins while inhibiting bradykinin and C-fibers, thereby altering pain perception<sup>7</sup>.

3  
4  
5 Other in-vitro studies have seen an increase in fibroblasts levels with LLLT and other studies have  
6 found lasers to have an angiogenic effect<sup>8</sup>. It is thought that the organelle, mitochondria, is the first  
7 to absorb the light energy from the laser. The charged mitochondria will increase its production of  
8 adenosine-triphosphate, which will in turn, increase cellular turnover including proliferation of  
9 fibroblasts, growth factors and tissue oxygenation<sup>9</sup>. In terms of clinical application, this suggests that  
10 areas affected by injury where an acidic medium prevails resulting in poor cellular proliferation can be  
11 treated by laser therapy<sup>5</sup>.

### 22 **The current evidence on LLLT**

23  
24  
25  
26 Examination of the evidence base revealed a systematic review and meta-analysis performed in 2012  
27 and updated in 2017<sup>7,10</sup>. Conclusions drawn stated that LLLT did not show net benefits but bore no  
28 adverse effects. Since publication of these reviews, new randomised controlled trials (RCTs) have been  
29 published.  
30  
31  
32  
33  
34  
35  
36

### 37 **Study question**

38  
39  
40  
41 A study question was formulated as such: Do individuals undergoing surgical removal of impacted  
42 mandibular third molars have less post-operative pain, swelling and trismus with administration of  
43 low-level laser therapy compared to placebo?  
44  
45  
46  
47  
48

### 49 **Hypotheses**

50  
51  
52  
53 The investigators hypothesised that LLLT is effective in reducing pain, swelling and trismus after third  
54 molar surgery. The null hypothesis is that administration of low-level laser therapy has no effect on  
55 post-operative pain, swelling and trismus following surgical removal of impacted mandibular third  
56 molars.  
57  
58  
59  
60  
61  
62  
63  
64  
65



## Study aims

The specific aims of this study were to systematically review and meta-analyse the evidence on whether administration of low-level laser therapy is effective in reducing post-operative pain, swelling and trismus in patients undergoing surgical removal of lower third molars compared to placebo.

## MATERIALS AND METHODS

### Study design

To address the research purpose, the investigators designed and implemented a systematic review modelled after the Cochrane Collaboration recommendations for systematic reviews, in accordance with the 'Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)' guidelines<sup>11</sup>.

The study population was composed of all publications on the topic of LLLT and surgical MTM removal up to May 2020. To be included in the sample, publications had to satisfy the following criteria: RCTs comparing efficacy of LLLT compared to placebo after surgical removal of third molars, LLLT operating at a wavelength between 600-1000nm of any regimen and reporting outcomes of pain, swelling or trismus. No restrictions were placed on subject characteristics. No language barriers were placed, and non-English texts were translated.

Publications were excluded from the analyses if they did not have a placebo arm or were non-human studies.

Due to the retrospective nature of this study, it was granted an exemption from formal ethical approval in writing by the University of Central Lancashire Institutional Review Board. This study has been registered on the website of the International Prospective Register of Systematic Reviews; PROSPERO; CRD42018112018<sup>12</sup>.

### Variables

## **Treatment group**

1  
2  
3 The treatment groups included subjects having received LLLT after surgical removal of MTMs. LLLT,  
4  
5 known as biostimulation, causes a photochemical effect that can upregulate metabolism resulting in  
6  
7 wound healing and reduce inflammatory processes. All lasers defined as low-level with a wavelength  
8  
9 of 600-1000nm were included. All laser types such as diode lasers, infrared lasers, helium-neon and  
10  
11 gallium-aluminium-arsenic lasers were included. The power generated by these respective lasers was  
12  
13 between 10-500mW. The duration of application were between 15 and 180 seconds with an energy  
14  
15 output between 3-12J/cm<sup>2</sup>. Laser emission was either continuous or intermittent. The timing of laser  
16  
17 therapy was either pre-operative, immediate post-operative or delayed post-operative, in either  
18  
19 single or multiple applications. The laser was applied either intra or extraorally or both. The authors  
20  
21 were not comparing efficacy of different laser types, wavelengths, power, energy output and duration;  
22  
23 therefore, outcomes involving these variables were pooled by calculating their weighted average  
24  
25 across the treatment arms. Subgroup analyses were performed for intraoral and extraoral laser  
26  
27 application.  
28  
29  
30  
31  
32  
33  
34

## **Control group**

35  
36  
37  
38 All subjects in control groups had placebo therapy. The placebo involved mimicking application of laser  
39  
40 therapy with absence of photon energy transfer.  
41  
42  
43

## **Predictor variables**

44  
45  
46  
47 The primary predictor variables were postoperative pain, swelling and trismus and were reported for  
48  
49 day 2 and day 7 postoperatively. For studies that did not include outcomes on these days, data  
50  
51 obtained from the closest time point was considered.  
52  
53  
54

55  
56 Pain can be defined as an unpleasant sensory and emotional experience associated with actual or  
57  
58 potential tissue damage. This outcome was assessed using the visual analogue scale (VAS). This patient  
59  
60  
61  
62  
63  
64  
65

1 reported outcome measure is an instrument that aims at measuring pain intensity and ranges across  
2 a continuum of values between 0 and 10. Mean postoperative pain values were used for meta-  
3 analyses.  
4  
5  
6

7  
8 Swelling or oedema is the result of fluid accumulation in the soft tissues. Measurement of swelling is  
9 challenging as it can present in different tissue planes and can be localised or diffuse. As such,  
10 measurements of swelling are rarely standardized. Subgroup analyses were conducted for the most  
11 used methods of swelling assessment; distance between tragus and commissure; distance between  
12 gonion and canthus and Amin & Laskin method (measured as distance between commissure and lower  
13 part of auricular lobe & distance between canthus and angle of mandible)<sup>13</sup>.  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Trismus describes the state of reduced mouth opening and is usually secondary to pain, swelling and  
24 pathology. It is measured in millimetres as the distance from the maxillary incisal edge to the  
25 mandibular incisal edge. Studies not using this method of assessment were not included in the meta-  
26 analyses.  
27  
28  
29  
30  
31  
32

### 33 **Other variables**

34  
35  
36  
37  
38 Intrinsic variables such as age, sex and pain sensitivity are well recognized modifiers of pain, swelling  
39 and trismus. Extrinsic variables in the form of co-interventions such as antibiotics, analgesics, steroids  
40 and mouthwashes can confound the findings by amplifying the effect of LLLT.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 **Search methods**

58  
59  
60  
61  
62  
63  
64  
65

1 A comprehensive search strategy was used and several databases were searched for published studies  
2 from inception of these respective databases to May 2020: Medline, Embase, Dentistry and Oral  
3 Sciences Source, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Academic Search  
4 Complete, Cochrane Library. Ongoing and unpublished trials were searched on: World Health  
5 Organization (WHO) International Clinical Trials Registry Platform (ICTRP). Internet-based databases  
6 were also searched: [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), [www.controlledtrials.com](http://www.controlledtrials.com), [www.scholar.google.co.uk](http://www.scholar.google.co.uk).  
7  
8 References from eligible published studies were scrutinised by hand searching: Journal of American  
9 Dental Association, International Journal of Oral and Maxillofacial Surgery, British Journal of Oral and  
10 Maxillofacial Surgery. Grey literature search was performed on 'OpenGrey'. Experts in the field were  
11 contacted if further information was required. Search was performed from conception of electronic  
12 databases. No search restrictions were placed at this stage. Search criteria can be found in Appendix  
13  
14 A.

### 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 **Data collection method**

30  
31  
32  
33 The results obtained from each of the 5 respective electronic databases were transferred to the  
34 referencing software Refworks®. Duplicate results were then eliminated. The title and abstracts of  
35 the remaining studies were then screened for eligibility and any non-relevant articles were excluded.  
36  
37 Potential salient trials were assessed in full text format and cross-referenced against inclusion and  
38 exclusion criteria. Trials not meeting the inclusion criteria were eliminated.  
39  
40  
41  
42  
43  
44

45  
46 This process was performed in duplicate by two independent reviewers. Disagreements were resolved  
47 by consensus and when no consensus could be reached, a third investigator acted as an arbitrator.  
48  
49  
50

51  
52 The final studies were evaluated by two investigators independently and in duplicate. Distillation of  
53 information was expediated using custom designed data extractions tables. The risk of bias in the  
54 included studies were evaluated using the Cochrane Risk of Bias Tool. Again, this was performed by  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 two reviewers independently to reach a mutual consensus. Risk was classified as low, high or unclear.  
2 If data was missing, the authors were contacted to obtain information.  
3  
4

## 5 **Data analyses**

6  
7  
8  
9 We pooled data statistically and conducted meta-analyses on available outcomes using a random-  
10 effects model. All analyses were undertaken, and forest plots created using Comprehensive Meta-  
11 Analysis software (version 3). Results were expressed as standardised mean differences (SMD) with  
12 95% confidence intervals (CI) for dichotomous outcomes. We performed statistical tests for  
13 heterogeneity based on  $I^2$  statistic. Relevant heterogeneity will be tested for using the  $I^2$  statistic and  
14 significant heterogeneity assumed if  $I^2$  is greater than 40% (i.e. more than 40% of the variability in  
15 outcome between trials could not be explained by sampling variation). We assessed for evidence of  
16 publication bias graphically using Funnel plots and statistically using Egger's test<sup>14</sup>.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 In the analysis of swelling, models were selected based on the methods of assessing swelling: method  
30 1 – distance between tragus and commissure; method 2- Amin & Laskin method; method 3 – distance  
31 between gonion and canthus.  
32  
33  
34  
35  
36

## 37 **RESULTS**

### 38 **Description of studies**

39  
40  
41  
42  
43 Four hundred and sixty-two results were obtained from the five databases searched. Hand searching  
44 produced 5 additional papers making a total of 467 papers. Eighteen studies were excluded at the full  
45 text screening stage with justification<sup>7,10,15-30</sup>. Seventeen studies met the inclusion criteria<sup>1,31-46</sup>. The  
46 flow of information is illustrated in a PRIMSA diagram, see Figure 1.  
47  
48  
49  
50  
51  
52

53 All 17 studies were randomised controlled trials. However, the study designs varied. Nine studies had  
54 a split-mouth design<sup>33-37,40-42,46</sup>. The rest of the studies had parallel designs<sup>1,31,32,38,39,43-45</sup>. All 17 studies  
55 followed study subjects for at least 7 days.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 A total of 1064 study subjects participated across the 17 studies. Two studies did not record participant  
2 gender and age<sup>31,43</sup>. The study subjects were aged between 16- 70 years and there were 370 recorded  
3  
4 female subjects. All studies took place in a hospital setting. The general characteristics of included  
5  
6 studies is presented in Table 1.  
7  
8  
9

10  
11  
12 All 1064 study subjects in the studies had surgical removal of their lower third molars followed by  
13  
14 either laser therapy or placebo. However, the LLLT regimens varied in the type of LLLT used, the  
15  
16 approach, power, site and duration of application. Table 2 presents the LLLT regimen employed within  
17  
18 each study. Several co-interventions were also employed within the studies. Subjects had prophylactic  
19  
20 antibiotic in nine studies<sup>1,32,34-37,42,44-46</sup>. Seven studies provided oral acetaminophen to be taken post-  
21  
22 operatively<sup>27,32,35,40,41,44,45</sup>. Six studies prescribed non-steroidal anti-inflammatory (NSAID) post-  
23  
24 operative medication<sup>1,34,36,37,42,46</sup>. All 17 studies had used placebo as a comparator<sup>1,31-46</sup>.  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Risk of bias of included studies**

34  
35  
36 Using the 'Cochrane Risk of Bias Assessment Toolkit', seven studies had adequate randomization  
37  
38 processes<sup>33-36,38,39,46</sup>. Ten studies stated that their study subjects were randomized but did not specify  
39  
40 their method of randomization<sup>1,31,32,37,40-45</sup>. One study discussed allocation concealment<sup>33</sup>. Three  
41  
42 studies mentioned that subjects were randomized only after the surgery was performed<sup>1,38,40</sup>. By  
43  
44 randomizing after the surgery, both the surgeon and patient would be unaware of future treatment  
45  
46 allocation. Surgeons were blinded in five studies<sup>33,34,37,38,42</sup>. Three studies used different surgeons to  
47  
48 perform the surgery and administer the laser, but it was unclear as to whether the surgeons were  
49  
50 blinded<sup>31,32,35</sup>. All study subjects in the 17 studies were blinded to the intervention they received<sup>1,31-46</sup>.  
51  
52  
53 Three studies had made available their study protocol<sup>31,33,38</sup>. In 16 studies, the prespecified outcomes  
54  
55 set out in the aims have been reported on and discussed<sup>1,31,32-38,40-46</sup>. One study carried out a sample  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 size calculation<sup>33</sup>. Treatment and follow-up protocols were the same for both treatment and control  
2 groups across the studies. Seven studies declared no interests<sup>1,31,32,34-36</sup> and three studies declared  
3 funding<sup>43,44,46</sup>. After consideration of each domain, calculation of an overall risk of bias for each study  
4 found that all 17 studies had a lower overall risk of bias<sup>1,31-46</sup>. Figure 2 illustrates a traffic light system  
5 to categorise the risk of bias for each respective domain for each study.  
6  
7  
8  
9

## 10 **Efficacy of LLLT**

### 11 **Pain**

12  
13  
14  
15  
16  
17  
18 Fifteen studies, with a total of 66 subjects, measured pain<sup>1,31,32-43,46</sup>. Ten studies found that LLLT  
19 reduces pain in subjects post-operatively<sup>1,32,35-38,40,41,46</sup>. Five of these studies reported that the pain  
20 reduction was statistically significant<sup>32,34,37,38</sup>. Three studies found no clinical nor statistical difference  
21 in pain levels between the treatment and control group<sup>31,33,43</sup>. In one study, LLLT showed higher pain  
22 scores compared to placebo in the four hours after surgery<sup>39</sup>. The included trials had a degree of  
23 variation in the times at which measurements were performed; the statistical analysis and the study  
24 designs. Saber et al., in addition to pain intensity, also measured pain duration. Laser group  
25 participants had shorter duration of pain compared to control groups in that study<sup>38</sup>.  
26  
27

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38 Five out of 15 studies that reported pain, demonstrated homogeneity and were included in meta-  
39 analyses. The results showed not significant reductions in standardised mean differences (SMD) for  
40 pain on day 2 and day 7 in the intervention group compared to the control group (SMD -0.502, 95% CI  
41 -1.038, 0.034; SMD -0.244, 95% CI -0.542, 0.053, respectively). See Figures 3 & 4. The funnel plot  
42 suggests there is potential publication bias based on asymmetry; however, the Eggers regression  
43 intercept suggests publication bias<sup>14</sup>. It is important to note however that this must be interpreted  
44 with caution as it has been suggested the use of this test with less than 10 studies reduces its power<sup>47</sup>.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 See Figure 5.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Swelling

Eleven studies, with a total of 380 subjects, looked at swelling as an outcome measure<sup>1,32,33,36,37,40,42-46</sup>.

The measurement of swelling differed across the studies. Most swelling measurements were taken as the distance between two facial points. Facial landmarks used were: tragus, commissure of mouth, gonion, canthus and auricular lobe. Two studies used the Amin and Laskin method<sup>44,45</sup>. Two studies used observed values<sup>42,43</sup>. One study used a 3-dimensional photogrammetric system to measure volumetric postoperative swelling<sup>32</sup>. Seven of these studies found clinically important reduction in facial swelling among the laser groups compared to the placebo groups<sup>1,32,36,37,42,43,44</sup>. Only 2 studies showed statistically significant reduction in swelling between laser and control group<sup>44,46</sup>.

Five out of 11 studies demonstrated homogeneity and were included in the meta-analyses. The overall analysis of these five studies demonstrated significant reductions in swelling with either intraoral or extraoral application of LLLT on day two in the models with swelling assessment method (SMD -0.557, 95%CI -0.925, -0.189 and SMD -0.611, 95%CI -0.988, -0.234, respectively). See Figures 6 & 7.

The overall analysis of the five studies also found significant reductions in swelling with both intra-oral and extra-oral application of LLLT in Aras et al. 2010 and with swelling coefficient as the method of swelling assessment in Eshghpour et al. 2016 on day 7 (SMD -0.513, 95%CI -0.776, -0.250 and SMD -0.532, 95%CI -0.795, -0.269, respectively). See figures 8 and 9.

Analysis of three studies that used tragus to commissure as the method of swelling assessment found a not significant reduction in swelling on day two (SMD -0.448, 95%CI -0.968, 0.071) and a statistically significant reduction on day seven (SMD -0.443, 95%CI -0.786, -0.101) in the LLLT group compared to the control group. See Figures 10 & 11.

Analysis of two studies that used Amin & Laskin method as their method of swelling assessment found significant reductions in swelling in either intraoral and extraoral LLLT groups compared to controls



1 on day two (SMD -0.760, 95%CI -1.326, -0.195 and SMD -0.931, 95%CI -1.448, -0.415, respectively)  
2 and day seven (SMD -0.667, 95%CI -1.172, -0.163 and SMD -0.740, 95%CI -1.247, 0.233, respectively).  
3  
4 See Figures 12, 13, 14 & 15.  
5  
6  
7  
8  
9

10 Analysis of two studies that used distance between gonion and canthus as their method of swelling  
11 assessment found a significant reduction with LLLT on day two (SMD -0.603, 95%CI -1.112, -0.094) but  
12 not on day seven (SMD -0.441, 95%CI -1.740, 0.858, respectively). See Figures 16 & 17.  
13  
14  
15  
16  
17  
18

### 19 **Trismus**

20 Eleven studies, with a total number of 398 study subjects, measured trismus<sup>1,32-34,36,39,41,43-46</sup>. Two of  
21 them found statistically significant reduction in trismus with laser group compared to placebo<sup>39,44</sup>. The  
22 most popular method of measurement was distance from upper central incisors to lower central  
23 incisors. One study measured percentage trismus<sup>39</sup> and one study used observed values<sup>43</sup>.  
24  
25  
26  
27  
28  
29  
30

31 Six out 11 studies, demonstrated homogeneity and were included in the meta-analyses. The results  
32 showed no difference between LLLT and control groups, regardless of site of laser in Aras et al 2009,  
33 2010 and day of assessment in Farhadi et al. 2017 were included in the models. Figures 18 & 19  
34 present respective results for day two (SDM 0.002, 95%CI -1.159, 1.163 and SDM 0.075, 95%CI -1.187,  
35 1.036) and Figures 20 and 21 for day seven (SDM 0.068, 95%CI -0.469, 0.605 and SDM 0.143, 95%CI -  
36 0.471, 0.758).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 66 **DISCUSSION**

1 The purpose of this study was to investigate the benefits of LLLT in post-operative healing after surgical  
2 exodontia. The authors hypothesized that LLLT was effective in reducing post-operative sequelae after  
3 oral surgery. The null hypothesis was that administration of LLLT had no effect on post-operative  
4 healing. The specific aims of this study were to systematically review and meta-analyse the evidence  
5 on whether administration of low-level laser therapy was effective in reducing post-operative pain,  
6 swelling and trismus in patients undergoing surgical removal of lower third molars compared to  
7 placebo.  
8

9  
10  
11  
12  
13  
14  
15  
16  
17  
18 Seventeen RCTs were included in the review<sup>1,31-46</sup>. Data was statistically pooled to achieve meta-  
19 analyses for each overall outcome.  
20  
21

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

The results of this study show statistically significant reduction in post-operative swelling with the use of LLLT compared to placebo after dental surgery. LLLT does not significantly reduce pain or trismus after surgery as compared to placebo.

While statistical significance indicates the reliability of the study results, clinical significance reflects its impact on clinical practice. Many studies included in this review generalised statements on clinically important differences and statistical significance as related to the outcome variables. However, no studies, described clear parameters on what they considered to be clinically significant.

Ten out of seventeen studies reported clinically important positive differences in pain levels with the laser group compared to the placebo group<sup>1,32,35-38,40,42,46</sup>. However, only five of these respective studies showed statistically significant improvement<sup>32,34,35,37,38</sup>.

Seven studies demonstrated clinical reduction in swelling in the LLLT over the control group<sup>1,32,36,42-44</sup>. However, only two of these demonstrated this reduction in swelling with LLLT over placebo to be statistically significant<sup>37,44</sup>. Investigators across the studies used different facial landmarks or observed values to measure swelling. This heterogeneity may account for the lack of consistency in the effectiveness of LLLT on swelling reduction.

1 From the eleven studies that reported on trismus as an outcome measure, two of them demonstrated  
2 statistically significant reduction in trismus in LLLT group compared to control<sup>39,44</sup>. Four of them found  
3 LLLT to have no net benefit in reducing trismus following third molar surgery<sup>1,32,33,36</sup>.

4  
5  
6  
7 With regards to extrinsic variables in the form of co-interventions, post-operative medication was  
8 given in most of the studies<sup>1,32-37,40-46</sup>. The medications included antibiotics, analgesia and  
9 mouthwashes. Co-interventions along with LLLT can certainly confound the findings. Due to the fact  
10 that co-interventions were the same in treatment and control groups, any size of treatment effect  
11 would be attributed to the laser alone. The lack of standardization in both intrinsic and extrinsic  
12 variables across the studies did not allow pooling of data and effect measurement.

13  
14  
15  
16  
17 All studies lasted at least seven days<sup>1,31-46</sup>. A seven day follow up period is appropriate as the sequelae  
18 of IMTM surgery is short lived<sup>36</sup>. Pain, swelling and trismus are at their highest in the first 2 to 3 days  
19 after surgery and mostly subsides by the seventh day.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30 Three studies received funding<sup>43,45,46</sup> and 7 studies declared no conflict of interests<sup>31,32,34-36,43,44</sup>. Three  
31 studies specifically stated that LLLT bore no negative outcomes<sup>33,35,36</sup>. Thus, it appears that application  
32 of LLLT is safe as there is no evidence to suggest otherwise.

33  
34  
35  
36  
37  
38 This systematic review and meta-analysis updated the evidence presented by Brignardello et al. and  
39 Dawdy et al on the use of low-level laser therapy in reducing the post-operative complications of pain,  
40 swelling, trismus following surgical removal of impacted third mandibular molars<sup>7,10</sup>.

41  
42  
43  
44  
45  
46 Brignardello et al. reported that LLLT was not effective in reducing pain and swelling, but effective in  
47 reducing trismus after removal of IMTMs compare to placebo<sup>7</sup>. Dawdy reported negligible benefits  
48 from LLLT<sup>10</sup>. This is not mirrored by the findings of this review which concluded a significant reduction  
49 in swelling but pain or trismus following surgery.

50  
51  
52  
53  
54  
55  
56 The recommendations stated by Brignardello et al. on the need for more well-reported RCTs with  
57 standardized methods and timings of evaluating the outcomes of interest appears to have been  
58

1 followed<sup>7</sup>. The new studies had low overall risk of bias, they administered laser therapy at the same  
2 time, most of them used the VAS for pain measurement and trismus measurements were  
3  
4 standardised.  
5  
6

7 This review had several strengths. First, the searches were conducted with high methodological rigour  
8  
9 involving comprehensive searches and including all available sources from five electronic international  
10  
11 databases. Characteristics of all search terms including MeSH and free keywords for this topic were  
12  
13 carefully identified and scrutinised. In addition, we contacted an international panel of experts. A  
14  
15 comprehensive search strategy would ensure that no relevant studies would be inadvertently  
16  
17 excluded.  
18  
19  
20

21  
22 Second, this review included 17 studies, totalling 1064 study subjects compared to Brignardello et al.  
23  
24 who reported on 10 studies involving 740 subjects<sup>7</sup>. Our significant sample size increases the study  
25  
26 power.  
27  
28

29  
30 Third, all included studies were high quality randomized controlled trials with low risk of bias. On the  
31  
32 pyramid of hierarchy of evidence, this is Level 1b evidence, which is the most robust type of empirical  
33  
34 evidence when assessing the outcome of an intervention.  
35  
36

37  
38 Fourth, all the subjects across the studies were treated in a hospital setting. This is in line with the fact  
39  
40 that surgical removal of MTMs require specialist intervention. Presumably, the level of competence  
41  
42 of the surgeons would be similar across the trials; which further standardizes the surgery. This ensures  
43  
44 that any difference in outcome assessment is down to the intervention (i.e LLLT) alone.  
45  
46  
47

48 All recruits across the studies required surgical removal of MTMs. This strict inclusion criteria ensured  
49  
50 that the outcome assessments were not confounded by differences in baseline characteristics. The 17  
51  
52 included studies were performed in several countries across the world. The results of this study are  
53  
54 therefore generalizable internationally as the study populations came from both economically  
55  
56 developed and less economically developed countries <sup>1,31-46</sup>.  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 The main limitations of this systematic review stem from the heterogeneity; both clinical and  
2 methodological of included populations, diversity of measuring outcomes and their definitions. The  
3  
4 results of both split mouth and parallel trials were pooled together. The significance of the  
5  
6 heterogeneity in study design is not known; however, despite differences in study approach, the  
7  
8 designs were of high quality and low risk of bias, minimizing risk of spurious findings.  
9

10  
11  
12 The non-significant data on pain and trismus does not mean that there is no efficacy of the  
13  
14 intervention compared with controls. Several factors may play a role, including small sample size  
15  
16 issues in our meta-analyses. Due to the heterogeneity of included studies, the conducted meta-  
17  
18 analyses need to be interpreted with caution.  
19

20  
21  
22 Despite the postulated benefits of LLLT after surgery, there are still barriers to its use and  
23  
24 implementation in oral and maxillofacial clinics. Implementation of laser treatment requires capital  
25  
26 investment in the form of equipment, training and clinical time. Furthermore, implementation of any  
27  
28 novel therapy has a significant learning curve. None of the studies have discussed the cost implications  
29  
30 and effectiveness of laser provision compared to pharmaceutical management. On the surface,  
31  
32 pharmaceutical management after removal of third molars appears to be a cost-effective option that  
33  
34 does not require additional investment. Estimates on the cost of a helium-neon laser is from \$14,000.  
35  
36  
37 Additional training costs make this a high initial investment therapy. So far, there is insufficient  
38  
39 evidence to recommend this investment as a standard of practice for oral surgery.  
40  
41  
42

43  
44 Furthermore, no studies have completed an oral health related quality of life (OHRQoL) assessment  
45  
46 on the use of LLLT following surgical removal of MTMs. The authors are therefore unable to comment  
47  
48 on the impact of LLLT on quality of life (QoL) following oral surgical procedures. As such, this would be  
49  
50 an area of interest for future research.  
51

52  
53  
54 In conclusion, adults undergoing surgical removal of impacted mandibular third molars have  
55  
56 significantly less postoperative swelling with administration of low-level laser therapy compared to  
57  
58 placebo. Adults undergoing surgical removal of impacted mandibular third molars do not appear to  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

have less postoperative pain and trismus with administration of low-level laser therapy compared to placebo.

Few studies have investigated the use of low-level laser therapy after surgical removal of impacted mandibular third molars; therefore, this study makes a significant contribution to the evidence base.

There is, however, not yet enough evidence to promote the investment involved with the routine use of laser therapy after third molar surgery.

Future, high quality RCTs with standardization of study designs, outcome measures and LLLT regimen, together with an investigation into its cost-effectiveness would serve to better advise patients, doctors and policy makers about the use of low-level laser therapy in patients undergoing removal of impacted mandibular third molars.

**Disclosure.** The authors did not report any interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## REFERENCES

1. Farhadi F, Eslami H, Majidi A, Fakhrzadeh V, Ghanizadeh M, KhademNeghad S. Evaluation of adjunctive effect of low-level laser therapy on pain, swelling and trismus after surgical removal of impacted lower third molar: A double blind randomized clinical trial. *Laser Ther.* 2017;26(3):181-187.

- 1 2. Sisk AL, Hammer WB, Shelton DW, Joy ED. Complications following removal of impacted third  
2 molars: The role of the experience of the surgeon. *Journal of oral and maxillofacial surgery*.  
3 1986;44(11):855-859.
- 4 3. McGrath C, Comfort M, Lo E, Luo Y. Changes in life quality following third molar surgery, the  
5 immediate postoperative period. *Br Dent J*. 2003;194(5):265-268.
- 6 4. Osunde O, Adebola R, Omeje U. Management of inflammatory complications in third molar  
7 surgery: A review of the literature. *African health sciences*. 2011;11(3).
- 8 5. Jawad MM, Qader STA, Zaidan A, Zaidan B, Naji A, Qader ITA. An overview of laser principle, laser-  
9 tissue interaction mechanisms and laser safety precautions for medical laser users. *Int J Pharmacol*.  
10 2011;7(2):149-160.
- 11 6. Bjordal JM, Johnson MI, Iversen V, Aimbire F, Lopes-Martins RAB. Low-level laser therapy in acute  
12 pain: A systematic review of possible mechanisms of action and clinical effects in randomized  
13 placebo-controlled trials. *Photomedicine and Laser Therapy*. 2006;24(2):158-168.
- 14 7. Brignardello-Petersen R, Carrasco-Labra A, Araya I, Yanine N, Beyene J, Shah PS. Is adjuvant laser  
15 therapy effective for preventing pain, swelling, and trismus after surgical removal of impacted  
16 mandibular third molars? A systematic review and meta-analysis. *Journal of oral and maxillofacial  
17 surgery*. 2012;70(8):1789-1801.
- 18 8. Posten W, Wrone DA, Dover JS, Arndt KA, Silapunt S, Alam M. Low level laser therapy for wound  
19 healing: Mechanism and efficacy. *Dermatologic surgery*. 2005;31(3):334-340.
- 20 9. Hamblin R, Deidova N. Mechanisms of low level light therapy. mechanisms for low-light therapy,  
21 edited by michael R. hamblin, ronald W. waynant, juanita anders. . 2006;6140.
- 22 10. Dawdy J, Halladay J, Carrasco-Labra A, Araya I, Yanine N, Brignardello-Petersen R. Efficacy of  
23 adjuvant laser therapy in reducing postsurgical complications after the removal of impacted  
24 mandibular third molars: A systematic review update and meta-analysis. *J Am Dent Assoc*.  
25 2017;148(12):887-902. e4.
- 26 11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and  
27 meta-analyses: The PRISMA statement. *Ann Intern Med*. 2009;151(4):264-269.
- 28 12. [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42018112018](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018112018). Accessed  
29 September,9, 2020.
- 30 13. Amin, M. M., & Laskin, D. M. (1983). Prophylactic use of indomethacin for prevention of  
31 postsurgical complications after removal of impacted third molars. *Oral surgery, oral medicine, oral  
32 pathology*, 55(5), 448-451.
- 33 14. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. *BMJ*.  
34 1997;315(7121):1533-1537.
- 35 15. Alan, H., Yolcu, Ü., Koparal, M., Özgür, C., Öztürk, S. A., & Malkoç, S. Evaluation of the effects of  
36 the low-level laser therapy on swelling, pain, and trismus after removal of impacted lower third  
37 molar. *Head & face medicine*. 2016;12(1), 25.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
16. Amarillas-Escobar ED, Toranzo-Fernández JM, Martínez-Rider R, et al. Use of therapeutic laser after surgical removal of impacted lower third molars. *Journal of oral and maxillofacial surgery*. 2010;68(2):319-324.
  17. Batinjan G, Filipovic Zore I, Rupic I, Bago Juric I, Zore Z, Gabric Panduric D. Assessing health-related quality of life with antimicrobial photodynamic therapy (APDT) and low level laser therapy (LLLT) after third molar removal. *J Lasers Med Sci*. 2013;4(3):120-126.
  18. Batinjan G, Zore Z, Čelebić A, Papić M, Pandurić DG, Zore IF. Thermographic monitoring of wound healing and oral health-related quality of life in patients treated with laser (aPDT) after impacted mandibular third molar removal. *Int J Oral Maxillofac Surg*. 2014;43(12):1503-1508.
  19. He W, Yu F, Li C, Pan J, Zhuang R, Duan P. A systematic review and meta-analysis on the efficacy of low-level laser therapy in the management of complication after mandibular third molar surgery. *Lasers in medical science*. 2015;30(6):1779-1788.
  20. Koparal M, Ozcan Kucuk A, Alan H, Asutay F, Avci M. Effects of low-level laser therapy following surgical extraction of the lower third molar with objective measurement of swelling using a three-dimensional system. *Experimental and therapeutic medicine*. 2018;15(4):3820-3826.
  21. Markovic A, Todorovic L. Effectiveness of dexamethasone and low-power laser in minimizing oedema after third molar surgery: A clinical trial. *Int J Oral Maxillofac Surg*. 2007;36(3):226-229.
  22. Pedreira AA, Wanderley FG, Sa MF, et al. Thermographic and clinical evaluation of 808-nm laser photobiomodulation effects after third molar extraction. *Minerva Stomatol*. 2016;65(4):213-222.
  23. Ong K, Ho V. Dental pain reduction by low level laser therapy: A double-blind controlled, randomized study in bilaterally symmetrical oral surgery. *Am J Pain Manage*. 2001;11(1):12-16.
  24. Pol R, Ruggiero T, Gallesio G, et al. Efficacy of anti-inflammatory and analgesic of superpulsed low level laser therapy after impacted mandibular third molars extractions. *J Craniofac Surg*. 2016;27(3):685-690.
  25. Raiesian S, Khani M, Khiabani K, Hemmati E, Pouretezad M. Assessment of low-level laser therapy effects after extraction of impacted lower third molar surgery. *J Lasers Med Sci*. 2017;8(1):42-45.
  26. Roynesdal A, Björnland T, Barkvoll P, Haanaes H. The effect of soft-laser application on postoperative pain and swelling: A double-blind, crossover study. *Int J Oral Maxillofac Surg*. 1993;22(4):242-245.
  27. Sampaio-Filho H, Sotto-Ramos J, Pinto EH, et al. Evaluation of low-level laser at auriculotherapy points to reduce postoperative pain in inferior third molar surgery: Study protocol for a randomized controlled trial. *Trials*. 2016;17(1):432.
  28. Taube S, Piironen J, Ylipaavalniemi P. Helium-neon laser therapy in the prevention of postoperative swelling and pain after wisdom tooth extraction. *Proc Finn Dent Soc*. 1990;86(1):23-27.
  29. Tuk JG, van Wijk AJ, Mertens IC, Keleş Z, Lindeboom JA, Milstein DM. Analgesic effects of preinjection low-level laser/light therapy (LLLT) before third molar surgery: A double-blind



1 randomized controlled trial. *Oral surgery, oral medicine, oral pathology and oral radiology*.  
2 2017;124(3):240-247.

3  
4 30. Verplanken M. Stimulation of wound healing after tooth extraction using low-intensity laser  
5 therapy. *Rev Belge Med Dent (1984)*. 1987;42(5):134-138.

6  
7 31. Sierra SO, Deana AM, Bussadori SK, et al. Effect of low-intensity laser treatment on pain after  
8 extraction of impacted mandibular third molars: A randomised, controlled, clinical trial. *British*  
9 *Journal of Oral and Maxillofacial Surgery*. 2015;53(10):996-1000.

10  
11 32. Asutay F, Ozcan-Kucuk A, Alan H, Koparal M. Three-dimensional evaluation of the effect of low-  
12 level laser therapy on facial swelling after lower third molar surgery: A randomized,  
13 placebocontrolled st. *Nigerian journal of clinical practice*. 2018;21(9):1107-1013.

14  
15 33. Sampaio-Filho H, Bussadori SK, Goncalves MLL, et al. Low-level laser treatment applied at  
16 auriculotherapy points to reduce postoperative pain in third molar surgery: A randomized,  
17 controlled, single-blinded study. *PLoS One*. 2018;13(6):e0197989.

18  
19 34. Hamid MA. Low-level laser therapy on postoperative pain after mandibular third molar surgery.  
20 *Ann Maxillofac Surg*. 2017;7(2):207-216.

21  
22 35. Kahraman SA, Cetiner S, Strauss RA. The effects of transcutaneous and intraoral low-level laser  
23 therapy after extraction of lower third molars: A randomized single blind, placebo controlled dual-  
24 center study. *Photomedicine and laser surgery*. 2017;35(8):401-407.

25  
26 36. Eroglu CN, Keskin Tunc S. Effectiveness of single session of low-level laser therapy with a 940 nm  
27 wavelength diode laser on pain, swelling, and trismus after impacted third molar surgery.  
28 *Photomedicine and laser surgery*. 2016;34(9):406-410.

29  
30 37. Eshghpour M, Ahrari F, Takallu M. Is low-level laser therapy effective in the management of pain  
31 and swelling after mandibular third molar surgery? *Journal of Oral and Maxillofacial Surgery*.  
32 2016;74(7):1322. e1-1322. e8.

33  
34 38. Saber K, Chiniforush N, Shahabi S. The effect of low level laser therapy on pain reduction after  
35 third molar surgery. *Minerva Stomatol*. 2012;61(7-8):319-322.

36  
37 39. Carrillo JS, Calatayud J, Manso FJ, Barberia E, Martinez JM, Donado M. A randomized double-  
38 blind clinical trial on the effectiveness of helium-neon laser in the prevention of pain, swelling and  
39 trismus after removal of impacted third molars. *Int Dent J*. 1990;40(1):31-36.

40  
41 40. Clokie C, Bentley KC, Head TW. The effects of the helium-neon laser on postsurgical discomfort:  
42 A pilot study. *J Can Dent Assoc*. 1991;57(7):584-586.

43  
44 41. Braams JW, Stegenga B, Raghoobar GM, Roodenburg JL, van der Weele LT. Treatment with soft  
45 laser. the effect on complaints after the removal of wisdom teeth in the mandible. *Ned Tijdschr*  
46 *Tandheelkd*. 1994;101(3):100-103.

47  
48 42. Fernando S, Hill C, Walker R. A randomised double blind comparative study of low level laser  
49 therapy following surgical extraction of lower third molar teeth. *British Journal of Oral and*  
50 *Maxillofacial Surgery*. 1993;31(3):170-172.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 43. Fikackova H, Navrátilová B, Dylevsky I, Navrátil L, Jirman R. Assessment of the effect of non  
2 invasive laser on the process of healing of an extraction wound by infrared thermography:  
3 Preliminary study. *J Appl Biomed*. 2003;1(6):175-180.

4 44. Aras MH, Gungormus M. The effect of low-level laser therapy on trismus and facial swelling  
5 following surgical extraction of a lower third molar. *Photomedicine and laser surgery*. 2009;27(1):21-  
6 24.

7 45. Aras MH, Gungormus M. Placebo-controlled randomized clinical trial of the effect two different  
8 low-level laser therapies (LLLT) "intraoral and extraoral" on trismus and facial swelling following  
9 surgical extraction of the lower third molar. *Lasers in medical science*. 2010;25(5):641-645.

10 46. López-Ramírez M, Vílchez-Pérez MÁ, Gargallo-Albiol J, Arnabat-Domínguez J, Gay-Escoda C.  
11 Efficacy of low-level laser therapy in the management of pain, facial swelling, and postoperative  
12 trismus after a lower third molar extraction. A preliminary study. *Lasers in medical science*.  
13 2012;27(3):559-566.

14 47. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel  
15 plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table 1. Characteristics of included studies.

Study	Design	Age	Gender	Intervention participants	Placebo participants
<b>Carillo et al., 1990</b>	Parallel	Mean 27	67F 33M	34	34
<b>Clokie et al., 1991</b>	Split-mouth	Range 16-25	10F 5M	15	15
<b>Fernando et al., 1993</b>	Split-mouth	Range 18-50	Not recorded	64	64
<b>Braams et al., 1993</b>	Split-mouth	Range 17-35	24F 19M	43	43
<b>Fikackova et al., 2003</b>	Parallel	Not recorded	Not recorded	1	1
<b>Aras et al., 2009</b>	Parallel	Range 18-27	21F 11M	16	16
<b>Aras et al., 2010</b>	Parallel	Range 18-27	34F 14M	32	16
<b>Lopez-Ramirez et al., 2017</b>	Split mouth	Range 18-37	11F 9M	20	20
<b>Saber et al., 2012</b>	Parallel	Range 18-70	50F 50M	50	50
<b>Sierra et al., 2015</b>	Parallel	Range 13-60	Not recorded	40	20
<b>Eroglu et al., 2016</b>	Split-mouth	Range 18-40	15F 20M	35	35
<b>Eshghpour et al., 2016</b>	Split-mouth	Range 18-35	24F 20M	44	44
<b>Kahraman et al., 2017</b>	Split-mouth	Range 16-35	36F 24M	60	60
<b>Farhadi et al., 2017</b>	Parallel	Range 18-35	24F 24M	24	24
<b>Hamid et al., 2017</b>	Split-mouth	Range 19-29	16F 14M	30	30
<b>Sampaio et al., 2018</b>	Split-mouth	Range 18-28	13F 29M	42	42
<b>Asutay et al., 2018</b>	Parallel	Range 17-29	25F 20M	15	15

Table 2. Low level laser therapy regimen employed across the included studies

Study	Type	Wavelength	Power	Energy	Site	Duration	Mode	Timing	Comparison
<b>Carillo et al., 1990</b>	He-Ne	632.8nm	0.3W/cm <sup>2</sup>	10J/cm <sup>2</sup>	Intraoral	Not recorded	Not recorded	Postoperatively	Placebo
<b>Clokie et al., 1991</b>	He-Ne	632.8nm	10mW	Not recorded	Intraoral	180s	Continuous	Postoperatively	Placebo
<b>Fernando et al., 1993</b>	Ga-Al-As	830nm	30mW	4J/cm <sup>2</sup>	Intraoral	132s	Intermittent	Postoperatively	Placebo
<b>Braams et al., 1994</b>	Ga-Al-As	829nm	30mW	NR	Intraoral	66s	Not recorded	Not recorded	Placebo
<b>Fikackova et al., 2003</b>	Ga-Al-As	830nm	200mW/cm <sup>2</sup>	12J	Intraoral	108s	Intermittent	10min, 1& 3 days after surgery	Placebo
<b>Aras et al., 2009</b>	Ga-Al-As	808nm	100mW	12J/cm <sup>2</sup>	Intraoral Extraoral	120s	Not recorded	Postoperatively	Placebo
<b>Aras et al., 2009</b>	Ga-Al-As	808nm	100mW	12J	Intraoral Extraoral	120s	Continuous	Postoperatively	Placebo
<b>Lopez-Ramirez et al., 2001</b>	Ga-Al-As	810nm	500mW	4j/cm <sup>2</sup>	Intraoral	32s	Continuous	Postoperatively	Placebo
<b>Saber et al., 2012</b>	Diode laser	810nm	100mW	5J/cm <sup>2</sup>	Intraoral	Not recorded	Continuous	Postoperatively	Placebo
<b>Sierra et al., 2015</b>	Red diode laser Infrared laser	652nm 808nm	100mW	106J	Intraoral Extraoral	120s 120s	Continuous	Not recorded	Placebo
<b>Eroglu et al., 2016</b>	Diode laser	940nm	275mW	50J	Extraoral	Time to reach 50J	Continuous	Postoperatively	Placebo
<b>Eshghpour et al., 2016</b>	Diode laser GA-Al-As	660nm 810nm	200mW	6J/cm <sup>2</sup>	Intraoral Extraoral	120s 90s	Continuous	Not recorded	Placebo
<b>Kahraman et al., 2017</b>	GA-Al-As	830nm	100mW	3J/cm <sup>2</sup>	Intraoral Extraoral	15s	Continuous	Preoperatively Postoperatively	Placebo

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

<b>Farhadi et al., 2017</b>	Diode laser	550nm	100mW	5J/cm <sup>2</sup>	Intraoral	25s	Continuous	Postoperatively	Placebo
<b>Hamid et al., 2017</b>	Ga-Al-As	810nm	100mW	9J	Intraoral	90s	Continuous	Postoperatively	Placebo
<b>Sampaio, 2018</b>	Red diode laser	660nm	100mW	6J	Extraoral	60s	Not recorded	Immediately, 24hr, 48hr postoperatively	Placebo
<b>Asutay, 2018</b>	Ga-Al-As	810nm	300mW	12J	Extraoral	40s	Continuous	Postoperatively	Placebo

**APPENDIX A**

#	Query
1	MH molar third
2	MH tooth impacted
3	MH tooth extraction
4	Exodontia
5	lower third molar
6	third molar
7	third molar surgery
8	t??th extract*
9	dental extraction
10	wisdom t??th
11	impact* t??th
12	mandibular t??th
13	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
14	MH low-level light therapy
15	MH laser therapy
16	MH lasers
17	laser*
18	laser irradiation
19	LLLT
20	laser therapy
21	low level light therapy
22	low level laser therapy
23	#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
24	MH pain
25	MH pain measurement
26	MH pain postoperative
27	pain
28	discomfort
29	postoperative pain
30	#24 OR #25 OR #26 OR #27 OR #28 OR #29
31	MH edema
32	edema
33	oedema
34	swelling
35	#31 OR #32 OR #33 OR #34
36	MH trismus
37	trismus
38	mouth opening
39	lock* jaw
40	#36 OR #37 OR #38 OR #39
41	treatment outcomes
42	wound healing
43	#34 OR #35

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

<b>44</b>	#30 OR #35 OR #40 OR #43
<b>45</b>	#13 AND #23 AND #44

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure 1. PRISMA diagram illustrating flow of information from search strategy to final included studies.

Figure 2: Risk of bias analysis of the included studies

Figure 3. Forest plot showing standardised mean differences and 95% CI for changes in pain reduction on day 2 after LLLT vs controls following third molar surgery (random-effects model).

Figure 4. Forest plot showing standardised mean differences and 95% CI for changes in pain reduction on day 7 after LLLT vs controls following third molar surgery (random-effects model).

Figure 5. Funnel plot showing SMD of pain reduction following LLLT intervention vs controls.

Figure 6 (overall). Forest plot showing standardized mean differences and 95% CI for swelling on day 2 after LLLT vs control following third molar surgery (random-effects model) [Aras Intra-oral laser]

Figure 7 (overall). Forest plot showing standardized mean differences and 95% CI for swelling on day 2 after LLLT vs control following third molar surgery (random-effects model) [Aras extra-oral laser]

Figure 8 (overall). Forest plot showing standardized mean differences and 95% CI for Swelling on day 7 after LLLT vs control following third molar surgery (random-effects model) [Eshghpour 2016 a = Distance between tragus and commissure (swelling coefficient) - Aras 2010 Intra-oral laser]

Figure 9 (overall). Forest plot showing standardized mean differences and 95% CI for Swelling on day 7 after LLLT vs placebo following third molar surgery (random-effects model) [Eshghpour 2016 a = Distance between tragus and commissure (swelling coefficient) - Aras 2010 Extra-oral laser]

Figure 10. Forest plot showing standardized mean differences and 95% CI for Swelling (tragus to commissure) measurement on day 2 after LLLT vs placebo following third molar surgery (random-effects model)

Figure 11. Forest plot showing standardized mean differences and 95% CI for Swelling (tragus to commissure) on day 7 after LLLT vs placebo following third molar surgery (random-effects model).

Figure 12. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin method) on day 2 after LLLT (intra-oral laser) vs control following third molar surgery (random-effects model)

Figure 13. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin method) on day 2 after LLLT (extra-oral laser) vs control following third molar surgery (random-effects model)



1 *Figure 14. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin*  
2 *method) on day 7 after LLLT (intra-oral laser) vs control following third molar surgery (random-*  
3 *effects model)*

4 *Figure 15. Forest plot showing standardized mean differences and 95% CI for swelling (Amin & Laskin*  
5 *method) on day 7 after LLLT (extra-oral laser) vs control following third molar surgery (random-*  
6 *effects model)*

7  
8  
9 *Figure 16. Forest plot showing standardized mean differences and 95% CI for swelling (gonion &*  
10 *canthus) on day 2 after LLLT vs control following third molar surgery (random-effects model)*

11  
12  
13  
14 *Figure 17. Forest plot showing standardized mean differences and 95% CI for swelling (gonion &*  
15 *canthus) on day 7 after LLLT vs control following third molar surgery (random-effects model)*


16  
17  
18 *Figure 18. Forest plot showing standardized mean differences and 95% CI for trismus on day 2 after*  
19 *LLLT vs control following third molar surgery (random-effects model) [For Aras 2010 extra-oral laser*  
20 *data used - Farhadi 2017 day 1]*

21  
22  
23  
24  
25 *Figure 19. Forest plot showing standardized mean differences and 95% CI for trismus on day 2 after*  
26 *LLLT vs control following third molar surgery (random-effects model) – [ For Aras 2010 intra-oral*  
27 *laser data used - Farhadi 2017 day 1]*

28  
29  
30 *Figure 20. Forest plot showing standardized mean differences and 95% CI for trismus on day 7 after*  
31 *LLLT vs control following third molar surgery (random-effects model) [ For Aras 2010 intra-oral laser*  
32 *data used]*

33  
34  
35 *Figure 21. Forest plot showing standardized mean differences and 95% CI for trismus on day 7 after*  
36 *LLLT vs control following third molar surgery (random-effects model) [For Aras 2010 extra-oral laser*  
37 *data used]*

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65




STUDIES

Carillo et al. 1990  
 Clokie et al. 1991  
 Fernando et al. 1993  
 Braams et al. 1994  
 Fikackova et al. 2003  
 Aras et al. 2009  
 Aras et al. 2010  
 Lopez-Ramirez et al.2012  
 Saber et al. 2012  
 Sierra et al. 2015  
 Eshghpour et al. 2016  
 Eroglu et al. 2016  
 Kahraman et al. 2017  
 Farhadi et al. 2017  
 Asutay et al. 2018  
 Sampaio et al. 2018  
 Hamid et al. 2018

+	-	+	+	-	-	+
-	-	+	+	+	+	-
-	-	+	+	-	-	+
-	-	+	+	+	-	+
-	-	+	+	-	-	+
-	-	+	+	+	-	+
-	-	+	+	+	-	+
+	-	+	+	+	-	+
+	+	+	+	+	+	+
?	?	+	+	+	+	+
?	?	+	+	+	+	+
+	?	+	+	+	+	+
+	?	+	+	+	+	+
?	+	+	+	+	+	+
?	?	+	+	+	+	+
+	+	+	+	+	+	+
+	?	+	?	+	+	+

Random sequence generation (selection bias)  
 Allocation concealment (selection bias)  
 Blinding of participants & personnel (performance bias)  
 Blinding of outcome assessment (detection bias)  
 Incomplete outcome data (attrition bias)  
 Selective reporting (reporting bias)  
 Other bias


DOMAIN




Study name	Statistics for each study			Sample size		Std diff in means and 95% CI	Relative weight
	Std diff in means	Lower limit	Upper limit	Experimental	Control		
Asutay 2018	-0.723	-1.482	0.016	15	15		12.69
Eroglu 2016	0.236	-0.234	0.706	35	35		
Eshghpour 2016	-0.334	-0.778	0.107	40	40		
Farhad 2017	-0.423	-0.986	0.140	24	24		
Kahraman 2017	-0.230	-0.775	0.315	28	28		
	-0.244	-0.542	0.053	140	140		

Heterogeneity:  $\tau^2 = 0.040$ ;  $\chi^2 = 6.138$ ,  $df = 4$  ( $P < 0.189$ );  $I^2 = 35\%$ ;


Favours experimental Favours control







Heterogeneity:  $\tau^2 = 0.080$ ;  $\chi^2 = 7.397$ ,  $df = 4$


( $P < 0.116$ );  $I^2 = 46\%$ ;














































# AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS

## Financial Relationships Disclosure Form

### *For Faculty, Authors, Committee/Board Members, Reviewers and Staff*

Organizations accredited by the American Dental Association Continuing Education Recognition Program (ADA CERP) and Accreditation Council for Continuing Medical Education (ACCME) are required to identify and resolve all potential conflicts of interest with any individual in a position to influence and/or control the content of CDE/CME activities. A conflict of interest will be considered to exist if: (1) the individual has a *'relevant financial relationship,'* that is, he/she has received financial benefits of any amount, within the past 12 months, from a *'commercial interest'* (an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients), and (2) the individual is in a position to affect the content of CDE/CME regarding the products or services of the commercial interest.

All individuals in a position to influence and/or control the content of AAOMS CDE/CME activities are required to disclose to the AAOMS, and subsequently to learners: (1) any relevant financial relationship(s) they have with a commercial interest, or (2) if they do not have a relevant financial relationship with a commercial interest.

Failure to provide disclosure information in a timely manner prior to the individual's involvement will result in the disqualification of the potential Faculty, Author, Committee/Board Member, or Staff, from participating in the CDE/CME activity.

Type of CME activity: JOMS Manuscript Submission

Title of Submission: The use of laser therapy to reduce postoperative morbidity following third molar surgery. A systematic review and meta-analysis.

Name: Farya Domah Date: 31.05.2020

Please check one to indicate your role:

Faculty  Author  Committee Member (specify: \_\_\_\_\_)  Board of Trustees

Reviewer  Staff  Other (specify: \_\_\_\_\_)

E-mail(required): faryaa@hotmail.com

#### **DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

**NO**-Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

**YES**-I have or  an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

#### RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)

Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)	Research Grant (including funding to an institution for contracted research)	Speakers' Bureau	Stock/Bonds (excluding Mutual Funds)	Consultant	Other (Identify)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

I affirm that the foregoing information is complete and truthful, and I agree to notify the AAOMS immediately if there are any changes or additions to my relevant financial relationships. During my participation in this activity, I will wholly support the AAOMS' commitment to conducting CDE activities with the highest integrity, scientific objectivity, and without bias. I agree that I will not accept any honoraria, additional payments or reimbursements beyond what has been agreed upon to be paid directly by the AAOMS in relation to this educational activity.

Electronic Signature\*:  Date: 31.05.2020

**Corresponding author**

*\*Electronic signature required from corresponding author only. It is the responsibility of the corresponding author to collect and submit all relevant conflicts of interest (or lack thereof) of all contributing authors at the time of the submission.*

\_\_\_ 1<sup>st</sup> Co-Author (if applicable)  
 Name: Raunaq Shah

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

**NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)					
Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)	Research Grant (including funding to an institution for contracted research)	Speakers' Bureau	Stock/Bonds (excluding Mutual Funds)	Consultant	Other (Identify)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\_\_\_ 2<sup>nd</sup> Co-Author (if applicable)  
 Name: Ulugbek Nurmatov

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

**NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)					
Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)	Research Grant (including funding to an institution for contracted research)	Speakers' Bureau	Stock/Bonds (excluding Mutual Funds)	Consultant	Other (Identify)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\_\_\_ 3<sup>rd</sup> Co-Author (if applicable)  
 Name: Nara Tagiyeva-Milne

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

**NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)					
Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)	Research Grant (including funding to an institution for contracted research)	Speakers' Bureau	Stock/Bonds (excluding Mutual Funds)	Consultant	Other (Identify)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



\_\_\_ 4<sup>th</sup> Co-Author (if applicable)  
 Name: \_\_\_\_\_

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

\_\_\_ **NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

	<b>RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)</b>				
<b>Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)</b>	<b>Research Grant (including funding to an institution for contracted research)</b>	<b>Speakers' Bureau</b>	<b>Stock/Bonds (excluding Mutual Funds)</b>	<b>Consultant</b>	<b>Other (Identify)</b>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\_\_\_ 5<sup>th</sup> Co-Author (if applicable)  
 Name: \_\_\_\_\_

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

\_\_\_ **NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

	<b>RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)</b>				
<b>Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)</b>	<b>Research Grant (including funding to an institution for contracted research)</b>	<b>Speakers' Bureau</b>	<b>Stock/Bonds (excluding Mutual Funds)</b>	<b>Consultant</b>	<b>Other (Identify)</b>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\_\_\_ 6<sup>th</sup> Co-Author (if applicable)  
 Name: \_\_\_\_\_

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITHIN 12 MONTHS OF DATE OF THIS FORM**

\_\_\_ **NO**—Neither I, nor any member of my immediate family, has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

**OR**

\_\_\_ **YES**—I have or \_\_\_ an immediate family member has a financial relationship or interest (currently or within the past 12 months) with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The financial relationships are identified as follows (if needed, attach an additional list):

	<b>RELEVANT FINANCIAL RELATIONSHIP(S) RELATED TO YOUR CONTENT (CHECK ALL THAT APPLY)</b>				
<b>Commercial Interest(s) (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.)</b>	<b>Research Grant (including funding to an institution for contracted research)</b>	<b>Speakers' Bureau</b>	<b>Stock/Bonds (excluding Mutual Funds)</b>	<b>Consultant</b>	<b>Other (Identify)</b>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>